Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Book Value/Share Growth AcceleratingAccelerating
Percentile Rank90
5Y CAGR-16.3%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
-16.3%/yr
Long-term compound
Percentile
P90
Near historical high
vs 5Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 28.77% |
| Q3 2025 | 3.68% |
| Q2 2025 | -9.15% |
| Q1 2025 | -10.34% |
| Q4 2024 | -8.65% |
| Q3 2024 | -6.75% |
| Q2 2024 | -6.35% |
| Q1 2024 | -0.75% |
| Q4 2023 | -7.09% |
| Q3 2023 | -2.02% |
| Q2 2023 | -2.12% |
| Q1 2023 | 6.98% |
| Q4 2022 | -6.47% |
| Q3 2022 | -4.82% |
| Q2 2022 | -2.49% |
| Q1 2022 | 3.65% |
| Q4 2021 | -3.23% |
| Q3 2021 | -10.60% |
| Q2 2021 | 101.43% |
| Q1 2021 | 53.47% |
| Q4 2020 | 69.99% |
| Q3 2020 | 1.45% |
| Q2 2020 | -1.71% |
| Q1 2020 | -10.36% |
| Q4 2019 | 22.75% |
| Q3 2019 | 8.66% |
| Q2 2019 | 18.12% |
| Q1 2019 | -19.07% |
| Q4 2018 | -17.42% |
| Q3 2018 | -13.72% |
| Q2 2018 | 3.38% |
| Q1 2018 | -13.31% |
| Q4 2017 | 3.10% |
| Q3 2017 | -0.06% |
| Q2 2017 | 8.23% |
| Q1 2017 | 4.50% |
| Q4 2016 | 204.03% |
| Q3 2016 | -23.52% |
| Q2 2016 | -21.88% |
| Q1 2016 | -21.14% |